Comparing two creams for children with mild to moderate eczema
Part of Genetic & congenital, Immune system & allergy, Skin clinical trials.
This study compares two creams for treating mild to moderate eczema in children: crisaborole 2% and tacrolimus 0.1%. It aims to see which one is more effective and safe for your child.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your child must be between 2 and 18 years old.
- Your child must have mild to moderate atopic dermatitis (eczema).
- Eczema must cover less than 30% of your child's body.
- No active skin infection (viral, bacterial, or fungal) at the treatment site.
- No use of topical steroids, calcineurin inhibitors, PDE4 inhibitors, or immunosuppressive medications in the past 2 weeks.
- No other chronic inflammatory skin conditions like psoriasis or seborrheic dermatitis that could interfere with the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study compares two prescription creams, tacrolimus and crisaborole, to see which works better and is safer for treating mild to moderate eczema over 8 weeks. Both creams are applied to the skin and are alternatives to steroids.
This study compares two prescription creams used to treat mild to moderate eczema (atopic dermatitis) in people aged 2 and older. The goal is to see which cream is safer and works better for reducing symptoms like itching and redness.
This study tests a new cream called crisaborole to see if it helps with mild to moderate eczema. You would apply the cream twice a day for four weeks.
This trial tests if two different moisturizing balms work equally well for treating mild to moderate eczema (atopic dermatitis) in children and adults. It may help find a more affordable or better-tolerated option.
This study tests a new ointment containing probiotics (good bacteria) to see if it helps with eczema in children. It is a cream that is applied to the skin, and the goal is to see if it reduces the itching and redness.
This study tests a daily pill, abrocitinib, to see if it safely reduces severe eczema (atopic dermatitis) in children aged 2 to under 6 years. It may help when creams or other treatments haven't worked well enough.
Hear when a new Atopic Dermatitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.